Hi Everyone! I have just become aware of this stock and I'm curious about PharmAust's venture into repurposing monepantel for human health, specifically targeting cancer and neurodegenerative diseases. While the success in clinical trials could positively impact their stock, I'm wondering if there are other factors to consider that might influence the company's market performance. Any insights or additional perspectives on this? I have a number of other stock related to cancer research but none related to MND etc. I am excited to get on board with this.
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-388
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $71.08K | 400.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 416575 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 176371 | 7 |
View Market Depth
| Last trade - 14.25pm 06/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |